Table 1.
Patient characteristics.
| Characteristic | N (%) |
|---|---|
| Patients | 16 (100) |
| Randomization sequence | |
| - ABC | 9 (56) |
| - CBA | 7 (44) |
| Adjuvant tamoxifen treatment | 16 (100) |
| Age (Median, IQR) | 45 (42–58) |
| Sex | |
| - Female | 15 (94) |
| - Male | 1 (6) |
| Race | |
| - Caucasian | 15 (94) |
| - Arabic | 1 (6) |
| Height (Median, IQR) | 171 (167–176) |
| Weight (Median, IQR) | 73 (65–91) |
| BMI (Median, IQR) | 25 (23–29) |
| WHO Performance Status | |
| - 0 | 13 (81) |
| - 1 | 3 (19) |
| Previous chemotherapy | |
| - Yes | 12 (75) |
| ○ TAC | 2 (13) |
| ○ AC - paclitaxel | 4 (25) |
| ○ FEC - docetaxel | 6 (37) |
| - No | 4 (25) |
| Previous RTx | |
| - Yes | 10 (63) |
| - No | 6 (37) |
| Tamoxifen dose | |
| - 20 mg | 15 (94) |
| - 30 mg | 1 (6) |
| Genotype | |
| - CYP3A4*22 | |
| ○ EM | 16 (100) |
| - CYP2D6 | |
| ○ EM | 7 (44) |
| ○ IM | 7 (44) |
| ○ PM | 1 (6) |
| ○ UM | 1 (6) |
Abbreviations: IQR = interquartile range; TAC = Docetaxel, doxorubicin, and cyclofosfamide; AC = doxorubicin and cyclofosfamide; FEC = 5FU, epirubicine, and cyclofosfamide; RTx = radiotherapy; EM = extensive metabolism phenotype; IM = intermediate metabolism phenotype; PM = poor metabolism phenotype; UM = ultra-rapid metabolism phenotype.